Add BrightSurf on Google Email

Impact Journals LLC


Systemic AL amyloidosis: Current approach and future direction

Researchers review current treatment updates for systemic light chain (AL) amyloidosis, highlighting the need for early diagnosis and effective maintenance therapy. The article discusses the relationship between AL amyloidosis and monoclonal gammopathy of undetermined significance (MGUS), emphasizing the importance of regular monitoring.

SourceImpact Journals LLC·JournalOncotarget·TypeCommentary/editorial·DateMay 5, 2023

Cancer prevention with rapamycin

Researchers discuss rapamycin's potential to delay cancer onset by slowing cell proliferation and tumor progression. The mTOR pathway is involved in both cancer and aging, making rapamycin a promising chemopreventive agent.

SourceImpact Journals LLC·JournalOncotarget·TypeCommentary/editorial·DateApr 17, 2023

Cancer-associated fibroblasts: Challenges and opportunities

Cancer-associated fibroblasts (CAFs) are a type of cell that plays a crucial role in the tumor microenvironment. The authors suggest that understanding CAFs is essential for developing effective cancer therapies. Research targeting CAFs has shown promise, but challenges remain due to their complex nature.

SourceImpact Journals LLC·JournalOncotarget·TypeCommentary/editorial·DateApr 5, 2023

Impact of cortactin in cancer progression

Researchers discuss cortactin's impact on cancer progression by modulating the Wnt5a/ROR1 signaling pathway. Cortactin expression is found in various cancers, including breast and chronic lymphocytic leukemia, suggesting its potential role in promoting metastasis.

SourceImpact Journals LLC·JournalOncotarget·TypeCommentary/editorial·DateApr 4, 2023

Oncotarget | Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells

A new review paper suggests that selective protection of normal cells from chemotherapy could increase the therapeutic window and improve outcomes for cancer patients. The authors propose using antagonistic drug combinations to kill drug-resistant cancer cells, reducing side effects and improving quality of life.

SourceImpact Journals LLC·JournalOncotarget·TypeLiterature review·DateMar 13, 2023